Regulatory Affairs • US FDA

510(k) Submission - Risk Analysis & Performance Summary

Published • • 16 min read

510(k) risk analysis and performance test summaries have to be written to the template CDRH actually expects, or the submission comes back with a deficiency letter over formatting, not substance.

A 510(k) submission package tends to be described by its exhibit numbers: the substantial equivalence comparison, the 510(k) summary, the performance document, each with its own expected page count and structure. What those numbers hide is that CDRH isn't just checking for content, it's checking for the template that content is supposed to arrive in.

Format is not an afterthought

It's tempting to treat the risk analysis summary and performance test template as containers for already-finished technical work, something to fill in after the real analysis is done. CDRH reviewers read a lot of these submissions, and a document that doesn't match the expected structure slows the review down, or stops it outright, regardless of how sound the underlying science is.

Delivering the templates required:
  • Comparing the subject device against the predicate's cleared indications for use
  • Comparing technological characteristics against the predicate, point by point
  • Citing FDA guidance directly rather than paraphrasing it
  • Organizing risk analysis, performance testing, and labeling into the applicable exhibits

Where formatting errors turn into deficiency letters

An FDA Refuse-to-Accept or Additional Information request doesn't always mean the science was wrong. Just as often, it's triggered by an incomplete substantial equivalence comparison or a missing required exhibit, formatting problems dressed up as substance problems. Getting the template right the first time avoids a review cycle that has nothing to do with whether the device actually works.

Substance still has to be there

None of this means the template matters more than the underlying analysis. Delivering the risk analysis summary and performance test template meant the technical comparison was real, the indications for use were genuinely equivalent, the characteristics genuinely comparable, just presented in the structure CDRH is set up to review efficiently.

The Real Takeaway

510(k) risk analysis and performance test summaries have to be written to the template CDRH actually expects.

Otherwise the submission comes back with a deficiency letter over formatting, not substance, and the real technical work sits waiting behind a preventable review cycle.

Done reading this sample?

Go back to my Articles page to find topics that might be of interest to you. Let me know if you want me to write about something specific.

Back to article archive